An Australian court passed a favourable order for Ranbaxy Laboratories in its patent proceedings against Pfizer with regard to 'Atorvastatin', a cholesterol-lowering drug. The Federal court had ruled that one of Pfizer's patents was invalid for inutility, false suggestion and misrepresentation in obtaining the grant of Australian patent. However, the court at the same instant delivered the verdict that a proposed Ranbaxy generic product under a different patent infringed Pfizer's basic 'Lipitor' patent. Mr. Jay Deshmukh, Ranbaxy's Senior Vice President-Global Intellectual Property, stated "We are pleased with this decision as it stands, as it advances the entry of Ranbaxy's generic drug 'Atorvastatin' in Australia to May 18, 2012."
ITAG Business Solutions Ltd. would not be held responsible for any opinion generated from views expressed in the article. The article are of personal use of technical experts and not necessary use of the organisation.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
